NEW YORK – Clinical-stage biopharmaceutical company Zentalis Pharmaceuticals said on Monday that it is partnering with Eli Lilly to evaluate Zentalis' ZN-c5, an investigational oral selective estrogen receptor degrader (SERD), in combination with Lilly's CDK4/6 inhibitor abemaciclib (Verzenio), in patients with estrogen receptor-positive, HER2-negative, advanced breast cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.